期刊
CURRENT DRUG TARGETS
卷 15, 期 1, 页码 32-52出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450114666140106095811
关键词
LKB1 (serine-threonine kinase 11, STK11); AMP-activated protein kinase (AMPK); tumor suppression; mutations; targeting therapeutics
资金
- National Cancer Institute [R01CA133053]
- Cervical Cancer SPORE Pilot Award
- Career Development Awards from NCI [P50CA098252]
- Biomedical Research Foundation
LKB1 (also known as serine-threonine kinase 11, STK11) is a tumor suppressor, which is mutated or deleted in Peutz-Jeghers syndrome (PJS) and in a variety of cancers. Physiologically, LKB1 possesses multiple cellular functions in the regulation of cell bioenergetics metabolism, cell cycle arrest, embryo development, cell polarity, and apoptosis. New studies demonstrated that LKB1 may also play a role in the maintenance of function and dynamics of hematopoietic stem cells. Over the past years, personalized therapy targeting specific genetic aberrations has attracted intense interests. Within this review, several agents with potential activity against aberrant LKB1 signaling have been discussed. Potential strategies and challenges in targeting LKB1 inactivation are also considered.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据